Key Highlights
• Around 1,900 workers at one Dr. Reddy's plant in Hyderabad make more than 100 generics, with 75% of nearly one billion monthly doses going to US patients.
• Generics make up 90% of US prescriptions, and 40% of them are made in India.
• An Indian industry group estimates most tablets and liquids made in India would cost at least four times as much to produce in the United States.
• A line supervisor at the plant earns USD 3,840 a year, less than one-tenth the average US pharmaceutical manufacturing salary.
A Plant That Supplies Millions of Americans
The F.T.O. U-3 factory in Hyderabad, India, is little known to most people, yet its products reach millions of Americans. About 1,900 workers employed by Dr. Reddy's Laboratories operate around the clock to make more than 100 generic drugs, including antihistamines, statins and antidepressants. Of the nearly one billion oral doses the plant produces each month, 75% go to patients in the United States.
The scale of India's pharmaceutical industry has made it a cornerstone of the global drug supply. In a high-volume, low-margin business, India's ability to make pills at a small fraction of the cost elsewhere presents a major hurdle for the United States as it tries to bring production home.
The Policy Push
President Donald Trump has said he wants generic drug production returned to America, using tariffs to pressure pharmaceutical companies. In a July social media post, he said he planned to impose a 100% tariff on generic drugs starting in 2028, followed by a 200% tariff a year later. Generics account for 90% of the drugs prescribed in the United States, and 40% of them are made in India.
On Tuesday, the United States imposed a new 100% tariff on certain pharmaceutical imports but exempted generic drugs and many other products. Doctors and supply chain experts say taxing imported generics would raise costs, spur rationing and lead to shortages of crucial drugs.
The Cost Gap
The secretary general of the Indian Pharmaceutical Alliance estimates that most tablets and liquids made in India would cost at least four times as much to produce in the United States. The chief executive of Piramal Global Pharma, who runs more than a dozen factories including in Europe and the United States, described the cost structures as mirror images of each other. In America, labor is the highest cost "by a wide margin," followed by energy and materials. In India, materials are the greatest cost and workers the least.
At the Hyderabad plant, a 23-year-old supervisor who oversees a line packaging generic metoprolol, a beta blocker prescribed to heart patients, earns USD 3,840 a year and uses part of her salary to pursue a bachelor's degree in pharmaceutical chemistry. One of her subordinates earns about USD 2,000 a year. Both make less than one-tenth the average salary of a pharmaceutical manufacturing worker in the United States.
Speed of Construction
India has other advantages. According to the Piramal chief executive, factories and processes that took four years to set up in the United States, Europe or Israel could be completed within a year in India. Israel is home to Teva Pharmaceutical Industries, the biggest generics maker. Customized equipment can be made in India in half the time it would take in Germany or Austria.
How India Built the Industry
India got its start in generics in the 1970s by prioritizing affordable drugs for its large and mostly poor population, at a time when Western multinational drug companies did not. For decades, India declined to recognize drug patents, while its manufacturers patented the processes they devised to reverse-engineer medicines sold in wealthier markets.
By the time India's patent law was brought into line with World Trade Organization standards in 2005, its companies had become experts at processing complex drugs and producing them for much of Asia, Africa and Latin America. Around the same period, Americans began embracing generics, which by 2004 accounted for more than half of prescriptions filled in the United States.
Different Incentives After Patent Expiry
The greatest profits come from patented drugs. The head of the Indian industry group contrasted the two markets: in the United States, once a drug goes out of patent, attention moves on, but in India entrepreneurs keep developing the product, and at high volumes manufacturers get better at making it.
The pipeline for Indian manufacturers is widening. According to the same industry head, 55 major patents worth USD 300 billion a year are set to expire in the United States over the next five to seven years.
Figures Behind the Advantage
The 75% share of Hyderabad output sent to US patients, the 40% share of US generics made in India, the estimated fourfold cost gap and the pay difference between Indian and US plant workers are the figures that frame the reshoring debate.






Please wait processing your request...